Quarterly ResultApr 30, 2026, 04:03 PM
ARDX Q1 Revenue +38% to $93.4M; IBSRELA +58%; Reiterates 2026 Guidance
AI Summary
Ardelyx reported strong Q1 2026 financial results with total product revenue increasing 38% year-over-year to $93.4 million. This growth was primarily driven by IBSRELA revenue, which rose 58% to $70.1 million. The company reiterated its full-year 2026 revenue guidance for both IBSRELA and XPHOZAH, maintaining a strong financial position with $238.1 million in cash. Additionally, Ardelyx advanced its pipeline with the ACCEL Phase 3 trial for IBSRELA and refinanced its existing debt.
Key Highlights
- Q1 2026 total product revenue grew 38% year-over-year to $93.4 million.
- IBSRELA Q1 2026 revenue increased 58% year-over-year to $70.1 million.
- XPHOZAH Q1 2026 revenue was $23.3 million.
- Reiterated 2026 IBSRELA revenue guidance of $410-$430 million.
- Reiterated 2026 XPHOZAH revenue guidance of $110-$120 million.
- Cash, cash equivalents, and investments totaled $238.1 million as of March 31, 2026.
- Net loss for Q1 2026 was $37.6 million, or $(0.15) per share.
- Refinanced existing debt in April 2026 for better overall terms.